학술논문
Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
Document Type
Abstract
Author
Callander, Natalie; Silbermann, Rebecca; Kaufman, Jonathan L.; Godby, Kelly N. ; Laubach, Jacob P ; Schmidt, Timothy Martin; Sborov, Douglas W ; Medvedova, Eva ; Reeves, Brandi; Dhakal, Binod; Rodriguez, Cesar ; Chhabra, Saurabh; Chari, Ajai ; Bal, Susan ; Anderson, Larry D., Jr.; Dholaria, Bhagirathbhai; Nathwani, Nitya; Hari, Parameswaran; Shah, Nina; Bumma, Naresh; Holstein, Sarah A.; Costello, Caitlin; Jakubowiak, Andrzej; Wildes, Tanya M. ; Orlowski, Robert Z.; Shain, Ken H.; Cowan, Andrew J. ; Pei, Huiling ; Cortoos, Annelore ; Patel, Sharmila ; Lin, Thomas S.; Giri, Smith; Costa, Luciano J.; Richardson, Paul G.; Usmani, Saad; Voorhees, Peter M.
Source
In Blood 15 November 2022 140 Supplement 1:10144-10147
Subject
Language
ISSN
0006-4971